OMERACT超声倡议:SpA和PsA中以共识为基础的附着点炎超声定义与评分的可靠性

2018-10-17 MedSci MedSci原创

Balint PV等研究者在2018年8月3日在Annals of the Rheumatic Diseases上在线发表一篇研究,旨在基于共识的超声定义评估脊椎关节炎(SpA)和银屑病关节炎(PsA)中附着点炎基本病变的可靠性,并评估其中哪些对附着点炎的定义和评分的影响最大。 该研究由11名超声医师对来自5例SpA/PsA患者4处两侧位置的40个附着点进行评价。对9个超声基本病变进行了二元评分

Balint PV等研究者在2018年8月3日在Annals of the Rheumatic Diseases上在线发表一篇研究,旨在基于共识的超声定义评估脊椎关节炎(SpA)和银屑病关节炎(PsA)中附着点炎基本病变的可靠性,并评估其中哪些对附着点炎的定义和评分的影响最大。 该研究由11名超声医师对来自5例SpA/PsA患者4处两侧位置的40个附着点进行评价。对9个超声基本病变进行了二元评分:低回声、肌腱插入增厚、边缘骨刺、钙化、侵蚀、骨不规则、滑囊炎、以及附着点炎内部和周围的多普勒信号(表1)。使用Kappa统计数据评估可靠性。并要求超声检查医师说明哪些病变可考虑为炎症性或结构性,以及应纳入针对附着点炎的最终定义中。仅将由至少75%的评估者认为是附着点炎的病变纳入最终的定义。 研究结果显示,除了边缘骨刺(55%)和骨不规则(54%)外,检出病变的患病率非常低。可靠性范围从低至高不等[增厚性附着点炎最低(kappa 0.1,95%CI:0~0.7),边缘骨刺最高(kappa 0.6,95%CI:0.5~0.7)]。当低患病率被调整后,所有病变的kappa值均增加,在肌腱插入(0.9

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738911, encodeId=56051e389113c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Sep 29 05:31:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038252, encodeId=c38f203825279, content=<a href='/topic/show?id=749f9e97583' target=_blank style='color:#2F92EE;'>#附着点炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97975, encryptionId=749f9e97583, topicName=附着点炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Sun Dec 09 08:31:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989425, encodeId=de52198942584, content=<a href='/topic/show?id=7033165e692' target=_blank style='color:#2F92EE;'>#SpA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16576, encryptionId=7033165e692, topicName=SpA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Dec 06 21:31:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271072, encodeId=3e3912e10726b, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 19 08:31:00 CST 2018, time=2018-10-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1738911, encodeId=56051e389113c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Sep 29 05:31:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038252, encodeId=c38f203825279, content=<a href='/topic/show?id=749f9e97583' target=_blank style='color:#2F92EE;'>#附着点炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97975, encryptionId=749f9e97583, topicName=附着点炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Sun Dec 09 08:31:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989425, encodeId=de52198942584, content=<a href='/topic/show?id=7033165e692' target=_blank style='color:#2F92EE;'>#SpA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16576, encryptionId=7033165e692, topicName=SpA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Dec 06 21:31:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271072, encodeId=3e3912e10726b, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 19 08:31:00 CST 2018, time=2018-10-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1738911, encodeId=56051e389113c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Sep 29 05:31:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038252, encodeId=c38f203825279, content=<a href='/topic/show?id=749f9e97583' target=_blank style='color:#2F92EE;'>#附着点炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97975, encryptionId=749f9e97583, topicName=附着点炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Sun Dec 09 08:31:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989425, encodeId=de52198942584, content=<a href='/topic/show?id=7033165e692' target=_blank style='color:#2F92EE;'>#SpA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16576, encryptionId=7033165e692, topicName=SpA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Dec 06 21:31:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271072, encodeId=3e3912e10726b, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 19 08:31:00 CST 2018, time=2018-10-19, status=1, ipAttribution=)]
    2018-12-06 gostraight
  4. [GetPortalCommentsPageByObjectIdResponse(id=1738911, encodeId=56051e389113c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Sep 29 05:31:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038252, encodeId=c38f203825279, content=<a href='/topic/show?id=749f9e97583' target=_blank style='color:#2F92EE;'>#附着点炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97975, encryptionId=749f9e97583, topicName=附着点炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Sun Dec 09 08:31:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989425, encodeId=de52198942584, content=<a href='/topic/show?id=7033165e692' target=_blank style='color:#2F92EE;'>#SpA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16576, encryptionId=7033165e692, topicName=SpA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Thu Dec 06 21:31:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271072, encodeId=3e3912e10726b, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 19 08:31:00 CST 2018, time=2018-10-19, status=1, ipAttribution=)]

相关资讯

抗TNF治疗会增加AS、PsA、SpA患者的结核病风险

根据美国风湿病学会年会上提交的调查结果显示,使用肿瘤坏死因子(TNF)抑制剂治疗的强直性脊柱关节炎(AS)、银屑病关节炎(PsA)和脊柱关节病(SpA)的患者,其患结核病的风险是一般人群的7倍! 来自斯德哥尔摩卡罗琳斯卡医学院传染病部门的Mirjam K. de Vries博士和同事们进行了这项研究,调查抗TNF治疗对AS、PsA和SpA患者的结核风险的影响。 该研究纳入38702例患

Golimumab治疗外周型SpA的疗效评估

根据美国风湿病学会年会上提出的研究结果,单克隆抗体戈利木单抗(golimumab)治疗外周型脊柱关节炎后,75%的患者经历临床缓解。 来自比利时根特大学教学医院的Philippe Carron博士和同事们对60例活跃的外周型脊柱关节炎(SpA)患者进行了研究,使用golimumab (Simponi, Janssen)或安慰剂治疗,评估诱导治疗后的吴无药物持续临床缓解和复发风险。 40